ArticleJournal for immunotherapy of cancer2022

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.

Taketo Kawai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.